Amvuttra is administered intravenously every three weeks [1]. The recommended dose for adults is 1,000 mg [1].
How is Amvuttra administered?
Amvuttra is given as an infusion into a vein, which is also known as an intravenous or IV infusion [1].
What is the recommended dosage of Amvuttra?
The standard recommended dose of Amvuttra for adult patients is 1,000 mg administered every three weeks [1].
What is Amvuttra used to treat?
Amvuttra is indicated for the treatment of adult patients with transthyretin amyloidosis (ATTR amyloidosis) [1]. This includes both hereditary (ATTRv) and wild-type (ATTRwt) forms of the disease [1].
What is transthyretin amyloidosis?
Transthyretin amyloidosis is a rare, progressive, and life-threatening disease caused by misfolded transthyretin (TTR) protein that forms amyloid deposits in various organs, including nerves and the heart [1]. This buildup can lead to significant health problems and organ damage.
Are there any special instructions for Amvuttra infusion?
Patients receiving Amvuttra need to be monitored during and after the infusion for signs of an infusion-related reaction [1]. The infusion rate should be adjusted if a reaction occurs, and in some cases, the infusion may need to be stopped [1].
Where can I find more information about Amvuttra and its patents?
Information regarding drug patents, including those for Amvuttra, can be found on DrugPatentWatch.com [2].
Sources
1. Amvuttra Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216607s000lbl.pdf
2. DrugPatentWatch.com